Authors
Claire Thompson, Samuel J Withey, Nina Tunariu, Chris Parker, Alison Tree, Alison Reid, Angela Pathmanathan, Julia Murray
Published in
The British journal of radiology. Jul 28, 2026. Epub Jul 28, 2026.
Abstract
Treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded, with evidence supporting prostate radiotherapy in low-volume disease. However, evidence for consolidative radiotherapy to residual sites in patients rendered oligometastatic after systemic therapy is lacking. Advanced imaging with WB-MRI and PSMA PET/CT enables more accurate assessment of tumour burden and response.
This feasibility study assessed response to initial systemic treatment with an ARPI or docetaxel in 29 patients with polymetastatic (>5 metastases) HSPC. PSA and WB-MRI response using MET-RADS-P criteria were recorded.
20/29 (69.0.%) of patients were down-risked to oligometastatic disease (≤5 sites) after a median of 5.5 (IQR 5-5.8) months, identified on WB-MRI. Median PSA was 0.2 ng/ml (IQR 0.1-0.7) in down-risked patients versus 1.5 ng/ml (IQR 1.1-84) in those not down-risked. Residual intraprostatic disease was seen in 55% (11/20) of down-risked patients.
Most patients were down-risked on WB-MRI, supporting the existence of an induced oligometastatic state and providing rationale for the STAR TRAP randomised trial (ISRCTN16448082), which will assess the role of consolidative radiotherapy in this setting.
WB-MRI correlates with PSA response and shows potential as an imaging biomarker in mHSPC in this small feasibility study.
PMID:
42517815
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0